Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that the National Cancer Institute (NCI) has initiated a Phase II clinical trial to evaluate the potential efficacy of the kinesin spindle protein (KSP) inhibitor, ispinesib (SB-715992), as a second-line treatment for patients with renal [click link for full article]
More...